Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) "CONDUCTOME"

Cerebral Primitive Tumor With Chirurgical Indication Clinical Trial

— CONDUCTOME  

Official title:

Magnetoencephalographic Study of Glial Tumors Electromagnetic Signature

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02077504
• Other study ID #: CONDUCTOME
• Status: Terminated
• Phase: Phase 1
• Start date: September 2013
• Est. completion date: January 5, 2018

Study information

• Verified date: May 2018
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the correlation between functional MEG analysis of the tumor and its periphery and the tumor stage and treatment response.

Description:

A better tumor grade definition would provide an optimized surgical care, prognosis and therapeutical response evaluation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 28
• Est. completion date: January 5, 2018
• Est. primary completion date: January 5, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• more or equal than 18 years old

• patient affiliated to social security or similarly regime

• informed consent form signed

• supra-tentorial primitive cerebral tumor

Exclusion Criteria:

• Pregnant women and lactating mothers

• Ward of court or under guardianship

• Adult unable to express their consent

• Person deprived of freedom by judicial or administrative decision

• Person hospitalized without their consent

• Person under legal protection

• Magnetic Resonance Imaging (MRI) contraindication (implanted material non MRI-compatible, ferro-magnetic foreign body, claustrophobia)

• Patients needed emergency medical care for other pathology

• severely altered general health (Performance Status 3 or 4)

Related Conditions & MeSH terms

• Cerebral Primitive Tumor With Chirurgical Indication
• Glioma

Intervention

Other:
• MEG and MRI
CONDUCTOME

Locations

Country	Name	City	State
France	CLINATEC	Grenoble

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) data in tumor grade prediction		1 week before exeresis
Primary	anatomopathologic and clinical data in tumor grade prediction		1 week after exeresis
Secondary	Measurement of molecules involved in glial cells neuralisation expression in tumor samples		Up to 1 month after surgery
Secondary	Tumoral growth modelisation from patient MEG and MRI data		Up to 1 month after surgery